Related references
Note: Only part of the references are listed.MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy
Fabricio de Carvalho et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells, Phosphorylation of KAP1, and DNA Damage Repair
Neehar Bhatia et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Lenalidomide in multiple myeloma: Current status and future potential
Hang Quach et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma
Caroline Pabst et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2010)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Djordje Atanackovic et al.
BLOOD (2007)
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors
K Noonan et al.
CANCER RESEARCH (2005)
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst et al.
BLOOD (2004)
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes
T Hayashi et al.
BLOOD (2003)
T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells
MV Dhodapkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
